The treatment options for multiple myeloma have evolved significantly over the years, providing patients with a range of therapies tailored to their specific circumstances. The choice of treatment often hinges on various factors, including the aggressiveness of the disease, individual prognostic indicators like genetic markers, the overall physical condition of the patient, and any pre-existing health issues that may affect treatment decisions. Current therapeutic strategies include several classes of drugs, each working through different mechanisms. Proteasome inhibitors (PIs) disrupt the protein degradation process within myeloma cells, thereby promoting their death. Immunomodulatory drugs (IMiDs) modulate the immune system and inhibit tumor growth by enhancing the body's natural anti-cancer responses. Monoclonal antibodies specifically target cancer cells, marking them for destruction by the immune system. In cases where patients are eligible, autologous stem cell transplantation remains a viable option, offering the potential for long-term remission by replacing damaged bone marrow with healthy stem cells from the patient's own body.

Despite these advancements, multiple myeloma continues to present significant challenges, as it often recurs even after initial successful treatment and remains an incurable disease. This highlights the urgent need for innovative therapeutic strategies that can effectively address resistance to existing treatments, ultimately aiming to improve patient outcomes and survival rates.

Multiple myeloma is characterized by the synthesis of monoclonal immunoglobulin (Ig) proteins or their fragments, known as M proteins, which have lost their biological functionality. (Kyle & Rajkumar, 2008; Palumbo & Anderson, 2011).

The proliferation of multiple myeloma cells results in the gradual displacement of normal bone marrow hematopoietic precursors, which are essential for the production of blood cells. This displacement not only hampers the normal hematopoiesis process but also leads to an overproduction of M-proteins, which can have detrimental effects on the body's systems. Key characteristics of multiple myeloma include osteolytic lesions (areas of bone destruction that can lead to fractures and significant pain). Patients often experience anemia due to the impaired production of red blood cells, making them more prone to fatigue and weakness. Moreover, the disease can significantly increase susceptibility to infections, as the immune system becomes compromised. Additional complications include hypercalcemia (characterized by abnormally high calcium levels in the blood), which can lead to nausea and confusion. Renal insufficiency or failure is another serious consequence, often arising from the effects of M-proteins on kidney function. Lastly, neurological complications can occur, manifesting as various symptoms ranging from peripheral neuropathy to more severe neurological deficits. Collectively, these manifestations highlight the complex and multifaceted impact of multiple myeloma on patients' health. (Korde et al., 2011; Palumbo & Anderson, 2011) In the year 2022, a total of 187,952 cases of Multiple Myeloma (MM) were documented across the globe, representing approximately 0.94% of all cancer cases reported internationally. This hematological malignancy exhibits notable geographical variations in its incidence rates. Notably, Asia accounted for the highest number of cases, with 73,870 reported instances, which corresponds to 39.3% of the global total. Europe and Northern America followed, with 50,092 cases (26.7%) and 37,050 cases (19.7%), respectively. Among the countries in the Eastern Mediterranean Region (EMRO), Pakistan has reported the highest rates of incidence (25.3%) and mortality (26.3%) for Multiple Myeloma (MM). In Pakistan, there were 1,846 new cases of Multiple Myeloma and 1,616 deaths attributed to this disease. These statistics highlight the clinical and epidemiological importance of MM both regionally and globally. They emphasize the ongoing need for research and healthcare strategies aimed at improving patient outcomes and understanding the factors contributing to the incidence and mortality of this complex disease. (Global Cancer Observatory, 2024).

Figure 01: Absolute numbers, Incidence of Multiple Myeloma in EMRO, both sexes, in 2022 (Global Cancer Observatory, 2024).

Figure 02: Absolute numbers, Mortality rate due to Multiple Myeloma in EMRO, both sexes, in 2022 (Global Cancer Observatory, 2024).

The treatment options for multiple myeloma have evolved significantly over the years, providing patients with a range of therapies tailored to their specific circumstances. The choice of treatment often hinges on various factors, including the aggressiveness of the disease, individual prognostic indicators like genetic markers, the overall physical condition of the patient, and any pre-existing health issues that may affect treatment decisions. Current therapeutic strategies include several classes of drugs, each working through different mechanisms. Proteasome inhibitors (PIs) disrupt the protein degradation process within myeloma cells, thereby promoting their death. Immunomodulatory drugs (IMiDs) modulate the immune system and inhibit tumor growth by enhancing the body's natural anti-cancer responses. Monoclonal antibodies specifically target cancer cells, marking them for destruction by the immune system. In cases where patients are eligible, autologous stem cell transplantation remains a viable option, offering the potential for long-term remission by replacing damaged bone marrow with healthy stem cells from the patient's own body.

Despite these advancements, multiple myeloma continues to present significant challenges, as it often recurs even after initial successful treatment and remains an incurable disease. This highlights the urgent need for innovative therapeutic strategies that can effectively address resistance to existing treatments, ultimately aiming to improve patient outcomes and survival rates.

4.2. BCMA B Cell Maturation Antigen (BCMA), also known as TNFRSF17, is a vital membrane protein intricately involved in the survival and proliferation of B lineage cells. This essential protein interacts with two key ligands: the proliferation-inducing ligand (APRIL) and the B-cell activating factor (BAFF). Both ligands play a crucial role in promoting the growth and longevity of plasma cells, which are critical components of the immune system (Tai & Anderson, 2015).

Recent research has highlighted the significant therapeutic potential of targeting BCMA as a treatment strategy for multiple myeloma (MM). Advances in this domain have led to the development of innovative BCMA-targeted therapies, including engineered CAR T-cell therapy and bispecific T-cell engagers. These groundbreaking approaches have demonstrated impressive efficacy in early-phase clinical trials, resulting in durable responses among patients with advanced, heavily pre-treated MM (Patel et al., 2004; Avery et al., 2003).

4.3. CAR-T Therapy The Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a groundbreaking advancement in the field of immunotherapy, specifically designed to harness the patient's own immune system to target and eliminate cancer cells. This innovative approach involves genetically modifying a patient's T cells so they can express a chimeric antigen receptor that specifically recognizes antigens present on the tumor cells.

Mechanism of Action The CAR-T process typically begins with the collection of T cells from the patient through a procedure known as apheresis. The collected T cells are then genetically engineered in a laboratory setting to produce Chimeric Antigen Receptors (CARs) that can recognize specific cancer markers, such as CD19, in B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma. Once engineered, these CAR-T cells are expanded in number and subsequently infused back into the patient. Upon reintroduction, the CAR-T cells patrol the body for cancer cells expressing the target antigen, initiating an immune response that can lead to cellular lysis of the malignant cells (June et al., 2018).

Clinical Efficacy CAR-T therapy has shown remarkable success, particularly in hematologic malignancies. For example, studies have reported overall response rates (ORR) exceeding 80% in patients with relapsed or refractory ALL after treatment with CAR-T cells targeting CD19 (Kymriah®) (Schuster et al., 2019). Similarly, in patients with large B-cell lymphoma, the CAR-T product axicabtagene ciloleucel (Yescarta®) also demonstrated impressive efficacy, with a median progression-free survival of 6.5 months and an ORR of 82% (Zuma-1 trial) (Zuma et al., 2017).

Inclusion Criteria

1. Male and female participants of age 18 years and above.
2. Patients with a confirmed diagnosis of multiple myeloma according to IMWG diagnostic criteria.
3. Received at least 3 prior multiple myeloma treatment lines of therapy or are double refractory to an IMiD and PI (refractory multiple myeloma as defined by IMWG consensus criteria). Note: induction with or without hematopoietic stem cell transplant and with or without maintenance therapy is considered a single line of therapy.
4. Measurable disease at Screening as per IMWG criteria.
5. ECOG Performance Status grade of 0 to 2.
6. Adequate organ function: ANC/platelets thresholds (unless cytopenias attributable to MM), LVEF ≥45%, adequate oxygenation; hepatic/renal criteria specified in Section 10.
7. Negative pregnancy test for women of childbearing potential; agreement to effective contraception.
8. Patients giving written informed consent to participate in the study after a full understanding of the implications and constraints of the study protocol.
9. Understand the content of the ICF, and voluntarily sign the ICF (If the participant is unable to sign the ICF on their own due to illiteracy, an impartial witness is needed).
10. The subject can understand the research process and is willing and able to comply with all research proposals and other requirements of the study.
11. Willing and able to adhere to the prohibitions and restrictions specified in this protocol.

Exclusion Criteria

1. Patients who will meet any of the following criteria will not be eligible to participate in the study.

1. Prior treatment with CAR-T therapy directed at any target. Any therapy that is targeted to BCMA.

2. Known active, or prior history of central nervous system (CNS) involvement, or exhibits clinical signs of meningeal involvement of multiple myeloma.

3. Stroke or seizure within 6 months of signing the ICF.

4. Uncontrolled active infection, including uncontrolled bacterial or fungal infection; active uncontrolled HBV/HCV/HIV.

5. Clinically significant cardiac disease (e.g., NYHA III/IV, recent MI), or severe pulmonary disease.

6. Recent allogeneic HSCT with active GVHD or ongoing immunosuppression.

7. Pregnant or breast-feeding, or planning to become pregnant while enrolled in this study or within 1 year after receiving study treatment.

8. Any other circumstances that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site, to understand informed consent, or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments.

   -

   Exclusion Criteria:

   -

IPD will be shared on request by email.

after 31st December 2027 till 31st December 2028

Access will be given by requesting PI by email